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Abstract Major advances in chronic heart failure (cHF) therapy
have been achieved and documented in adult patients, while
research regarding the mechanisms and therapy of cHF in chil-
dren has lagged behind. Based on receptor physiological studies
and pharmacological knowledge, treatment with specific ß1-ad-
renergic receptor blocker (ARB), tissue angiotensin-converting
enzyme inhibitor (ACE-I), and mineralocorticoid antagonists
have to be recommended in children despite lack of sufficient
data derived from prospective randomized studies. At our insti-
tution, bisoprolol, lisinopril, and spironolactone have been firmly
established to treat systolic cHF, hypoplastic left heart syndrome
(HLHS) following hybrid approach and congenital left-right
shunt diseases, latest in patients where surgery has to be delayed.
Chronic therapy with long-acting diuretics and fluid restriction
are not advocated because short-term effects are achieved at the
expense of further neuro-humoral stimulation. It remains unclear
why diuretics are recommended although evidence-based stud-
ies, documenting long-term benefit, aremissing. However, that is
true for all currently used drugs for pediatric cHF.
Conclusion: This review focuses on the prevailing
Bnihilism^ of cHF therapy in children with the goal to encour-
age physicians to treat pediatric cHF with a rationally de-
signed therapy, which combines available agents that have
been shown to improve survival in adult patients with cHF.
Because of the lack of clinical trials, which generate the need-
ed evidence, surrogate variables like heart and respiratory rate,
weight gain, image-derived data, and biomarkers should be
monitored and used instead. The recommended pharmaco-
logical therapy for systolic heart failure is also provided
as the basis for utilizing reversible pulmonary arterial
banding (PAB) as a novel strategy in young children
with dilative cardiomyopathy (DCM) with preserved
right ventricular function.
What is Known:
• Heart failure (HF) in children is a serious public health concern.
• HF has numerous etiologies, but unspecific symptoms.
• HF interplays among neuro-humoral, and molecular abnormalities.
• Pediatric cHF-therapy is currently based on loop-diuretics, fluid
restriction and digoxin.
What is New:
• Cardiac function analysis has to include cardiac synchrony and VVI.
•Considering enormous potential of cardiac regeneration, therapy has to
extend with selective ß1-ARB, tissue ACE-I and mineralocorticoid
blockers, loop-diuretics avoided as ever possible.
• Inhibition of the endogenous neuro-humoral stimulation is monitored by
surrogate parameters as heart and breath rate and systolic and
diastolic blood pressure.
• Advocated HF therapy serves for regenerative strategies as reversible
Pulmonary Artery Banding in DCM.
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Abbreviations
ACE-I Angiotensin-converting enzyme inhibitor
ARB Adrenergic receptor blocker
BAR ß-Adrenergic receptor
BNP Brain natriuretic peptide
cHF Chronic heart failure
CHF Congestive heart failure
DCM Dilative cardiomyopathy
HFpEF Heart failure with preserved ejection fraction




NYHA New York Heart Association
RAA-S Renin-angiotensin-aldosterone system
RV Right ventricle
VSD Ventricle septum defect
VVI Ventricular-ventricular interaction
Considerations
BScience is neither dogmatic nor democratic!^
Heart failure is the final stage of a wide variety of cardiac
diseases. Symptoms of HF develop, once the heart becomes
unable to meet the metabolic demands of the body.
In adults, heart failure is frequently called the new epidemic
of the twenty-first century [36]. Causes of heart failure in
childhood are associated to congenital heart diseases, cardio-
myopathies, and arrhythmias as well as acquired heart and
circulatory diseases [21]. Epidemiological studies covering
the pediatric age group are very rare. More than 20 years
ago, Rodeheffer et al. [46] reported an incidence of four in-
fants <1 year of age in 1000 person years and a prevalence in
children <10 years of age of 1.3 in 1000.
Hsu and Pearson summarized the various causes of pediat-
ric heart failure [21] as well as the current treatment and future
directions [22].
Considering that cardiac output (flow) is based on heart
rate, myocardial contractility, preload, afterload, synchrony,
and ventricular-ventricular interaction (VVI), a low cardiac
output might be associated with heart failure due to one or
all of these variables (Fig. 1).
If there is no successful strategy to remove the root cause,
the aims of chronic congestive heart failure (CHF) therapy are
to modify the neuroendocrine responses that worsen CHF and
their pathophysiological consequences and to stimulate en-
dogenous repair mechanisms.
Established therapies in adults aim at reducing preload,
afterload, and neuro-humoral activation and to halt the ongo-
ing loss of cardiomyocytes, which gives way to replacement
fibrosis [7]. In Table 1, therapeutic goals for chronic HF treat-
ment in children are summarized.
In this context, tachy- and brady-arrhythmias need to be
prevented and if present effectively treated; sinus rhythm heart
rate needs to be adjusted to the lowest effective level in order to
reduce myocardial oxygen demand and to optimize the diastolic
ventricular filling time. Chronic stimulation of a dysfunctional
myocardium is counterproductive; all exogenous therapeutic
strategies that stimulate the neuro-humoral system have been
repeatedly analyzed and ought to be, whenever possible, omitted
(for example: chronic treatment with loop-diuretics); if inotropic
agents and vasoconstrictors become necessary, they should be
used as short as possible or as a bridge towards heart transplant,
if cardiac assist devices are not the better option.
Considering the balance of oxygen delivery and consumption,
positive inotrope vasodilators (milrinone, levosimendane) ought
to be preferentially used as long as myocardial perfusion pres-
sures are not compromised. During catecholamine infusion ther-
apy, strategies designed to protect the myocardium should be
considered, for example: a combination of epinephrine or nor-
epinephrine infusion with ß1-receptor blockers. In decompensat-
ed systolic heart failure, which often occurs in infants and chil-
dren with dilated cardiomyopathy, short-term epinephrine infu-
sion combined with intravenous or oral ß1-receptor blocking
agents (metoprolol, bisoprolol) is not a contradiction, but an ac-
tually used and recommended strategy [43]. In addition, it has to
emphasize that the right and left heart does not act in isolation;
cardiac re-synchronization [35] as well as strategies to improve
the ventricular-ventricular interaction (VVI) is desirable in order
to allow endogenous cardiac repair, in particular in younger pa-
tients [53, 61].
Bridging to heart transplantation (HTX), with or without
the use of assist devices, or transiting the patient from an acute
to a chronic heart failure status might be the therapeutically
strategy of choice, if no satisfactory return to normal function
can be achieved [53].
Differences of chronic HF treatment in children
and adults
Age- and perhaps mechanism-independent chronic HF is associ-
ated with neuro-humoral activation and increased levels of circu-
lating neuro-hormones (noradrenaline, adrenaline, renin, angio-
tensin II, aldosterone, vasopressin), which lead to vasoconstric-
tion, sodium, and water retention. Continuous endogenous
neuro-humoral activation leads to myocardiocyte apoptosis, ne-
crosis, and cardiac fibrosis, themain causes of chamber dilatation
and progressive dysfunction, culminating in a vicious cycle of
ever worse quality of myocardium and heart function [51].
Medical treatment recommendations for chronic HF in adults
have been based on controlled, randomized studies [29]. Large
cohort studies were necessary to pinpoint that among a group of
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HF treatment drugs as ß-adrenergic receptor blockers [2, 3, 40],
angiotensin-converting enzyme (ACE) inhibitors [1] and aldo-
sterone receptor antagonists [41] significantly reduce the mor-
tality by counteracting the neuro-humoral overdrive of chronic
HF. Such large cohort clinical trials cannot realistically be con-
ducted in children with chronic heart failure due to the small
patient numbers and the heterogeneity of the HF causes. Clinical
trials in the pediatric age group are generally underpowered and
cannot detect significant impact differences on survival rates.
Several review articles address the differences in responses to
medications in relation to the age of patients, pharmacokinetic/
pharmacodynamic characteristics, and underlying causes of
CHF and their molecular characteristics [48, 51]; however,
the overall strategy to block the neuro-humoral axis is not
disputed. Rossano and Shaddy [48] pointed to the missing
data in children and emphasized that extrapolating evidence
from adult patients to children with heart failure may have
limited utility. However, given the state of our current situa-
tion of pediatric heart failure therapy, this statement lacks a
forward-looking attitude and encourages a not-justified thera-
peutic Bnihilism^ when it comes to chronic HF treatment in
children. Unfortunately, this entirely uncreative state of the
affairs has been cultivated over decades [49].
In adults with chronic HF, new therapeutic strategies like
angiotensin-neprilysin inhibition have been lauded as a paradigm
shift in HF therapy [30], while in children, the use of ACE
inhib i tors , ß-adrenerg ic receptor b lockers , and
mineralocorticoid-receptor blockers still remains controversial
and—if recommended—is rarely used [60]. This then begs the
question, why effective therapy is being withheld in infants and
children despite well-designed and sufficiently powered random-
ized trials in adults, which have been published more than a
decade ago? In fact, drugs shown to be highly effective in adult
heart failure patients have been discredited because of their use in
studies with an unfortunate design, despite or because of their
administration in controlled, randomized, double-blind trials
which are acknowledged as the gold standard in evidence-
based medicine. In one single controlled randomized study, the
ACE inhibitor enalapril was judged to be not effective for the
treatment of univentricular heart failure [23]; this study has been
frequently cited to support the notion that ACE inhibitors are ill-
advised in the treatment of all children with HF. ß-Adrenergic
receptor (BAR) blockers have also been labeled to be of no
benefit for children with chronic HF; the potential use of highly
selective or non-specific BAR blocker has not been considered.
In one, highly cited BAR-blocker study in children, the effect of
carvedilol was assessed in 106 patients, while placebo was ad-
ministered to 54 children with functional classes II and III [56].
This study, performed in 26 North American pediatric heart cen-
ters, was not stratified according to the causes and severity of HF
and terminated after 5 years; in addition, there was no control for
co-medications; the dosage of diuretic drugs and whether the
BAR-blocker dose was adequate had not been or monitored by
simply observing the heart rate response. Remarkably, during the
same time period in US pediatric heart centers, BAR blockers
were routinely used only in 4 % of children with cHF [60]. This
fact illustrates what little clinical experience there is with BAR-
blocker therapy in children with cHF.
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CO = HR x SV
CO = VO2 / Ca-vDO2
VO2 = CO x Ca-vDO2
CaO2 = 1.34 x Hb x SaO2
DO2 = CO x CaO2
Fig. 1 Parameters responsible for
cardiac output. In addition to heart
rate, contractility, preload, and
afterload, cardiac synchrony as
well as ventricular-ventricular in-
teraction (VVI) defines cardiac
function. CaO2 oxygen content,
Ca-vDO2 arterial-venous oxygen
content difference, CO cardiac
output, DO2 oxygen delivery, HR
heart rate, SaO2 arterial oxygen
saturation, SvO2 venous oxygen
saturation in superior and inferior
caval vein, SV stroke volume,
VO2 oxygen consumption
Table 1 Therapeutic goals for chronic HF treatment in children
1. Preload optimization by avoiding intravascular, in particular intra-
arterial, volume depletion
2. Reduction of the systemic vascular resistance without jeopardizing the
coronary perfusion pressure
3. Optimizing myocardial oxygen consumption and re-establishing
myocardial synchrony as well as VVI
4. Allowing time to establish endogenous and exogenous repair
mechanisms
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The third thrust of HF therapy should decrease the endoge-
nous neuro-hormonal response by mineralocorticoid antago-
nism. In the RALES trial [41], treatment with spironolactone,
in addition to conventional therapy, led to a relative reduction
of the risk of death by 30 % and of cHF-related hospitalizations
by 35 % in adults. In pediatric patients, spironolactone is a com-
mon component of diuretic regimens due to its potassium-
sparing property but seldom used as a tissue aldosterone antago-
nist to influence cardiac re-remodeling, in particular myocardial
fibrosis. The Canadian guideline reports that therapy with drugs
that block the effects of aldosterone is well established in adults
with systolic HF; Bdata regarding the role of spironolactone or
related agents in the treatment of children with cHF are very
limited^ [25]. However, the few pediatric data published by
Masutani et al.—with a focus on the importance of
aldosterone-blocking drugs like spironolactone in children with
HF, and in particular with preserved ejection fraction (HFpEF),
have been widely ignored [28]. On the other hand, since 1978,
Engle et al. [16] had administered 137 courses of furosemide to
106 hospitalized pediatric patients with salt and water retention
associated with cardiac or renal disease; furosemide is by far the
most commonly used and recommended drug, not only for acute
but also for chronic heart failure in children. The diuretics are
recommended as effective and safe in the pediatric age group
when administered acutely as a parenteral medication and over
a long-term course by the oral route in the doses and at the time
intervals used in this study [16]. Yet, despite a lack of evidence-
based studies, the use of diuretics is supported by Cochrane’s
systematic review [18] as sufficient for the routine use in children
with chronic CHF. While there is a recognized lack of evidence
with regard to the use of ACE inhibitors, BAR blockers, and
mineralocorticoid antagonists in pediatric patients, the chronic
use of diuretics has never been scrutinized by pediatric opinion
leaders [25]. A similar situation prevails with regard to digoxin
treatment of chronic heart failure in infants and children. Again, a
randomized, placebo controlled study is only available for adult
patients with ischemic or cardiomyopathic CHF. Digoxin had
shown weak, but positive effects on left ventricular ejection frac-
tion (EF), exercise capacity, quality of life, and reduction of hos-
pitalizations, but the survival rate in the whole cohort was not
significantly improved [14]. In the pediatric literature, we find
several early clinical observational studies, which demonstrated a
beneficial effect on CHF, including improved contractility and a
decreased neuro-hormonal stimulation. Perhaps the Na/K-
ATPase inhibitor digoxin, as a positive inotropic drug might be
indicated in younger patients. On the other hand, a recently pub-
lished study of 48 infants with chronic HF secondary to left-to-
right shunt lesions who were randomized to treatment with enal-
april and furosemide ±, digoxin did not find any clinical improve-
ment. It was concluded that digoxin does not provide any extra
benefit in the treatment of such patients [15]. In considering the
results of this latter study, the Canadian guidelines for pediatric
chronic HF did not recommend digoxin in children with chronic
HF [25]. However, digoxin is a weak vasoconstrictor and co-
therapy with a neuro-hormonal axis-stimulating diuretic is from
our point of view not indicated for HF due to a left-right shunt
because the shunt flow is favored.
In conclusion: HF drugs need a clearly defined indication
and a convincing rationale. Simply, a randomized, placebo
controlled study design—which is highly desirable—howev-
er, lacking a crisp definition of the clinical target and the un-
derlying disease mechanism does not allow us to generate the
needed outcome information. One wonders also why the ef-
fectiveness of a chronic HF drug is not reported, as it is cus-
tomary for the drugs targeting pulmonary arterial hypertension
[29]; i.e., if the drug does not significantly alter the mortality,
then surrogate endpoints which demonstrate improvement of
the clinical status should be obtained to support their use. PH-
targeting drugs are not being withheld if they do not affect
mortality but improve the clinical functional class [26, 61].
Recommendations to improve chronic HF treatment
in infants and children
Systolic dysfunction related to left ventricular dilated
cardiomyopathy
The incidence of childhood cardiomyopathy is in the range of
1.13–1.24 per 100,000 children according to the data collected
by two population-based registries, where dilated cardiomyop-
athy accounts for more than half of the primary causes [6, 27].
Dilated cardiomyopathy (DCM) is a serious disease. The 1-year
and 5-year rates of death or transplantation were first described
to be 35 and 49 %, respectively, in a population-based study in
1998 and 31 and 46 % in the largest population study in 2006
[39, 56]. Recently, we described in a single-center study a lower
rate for death of 18 % and transplantation 31 % [50], which is
perhaps the result of an improved treatment strategy (Fig. 2).
While the overall goal of the treatment of children with DCM is
to avoid death or delay heart transplantation, different survival
rates after the diagnosis of DCM may be attributed to different
treatment strategies. Prior to treatment, a detailed diagnostic
workup is needed for left ventricular (LV)-DCM: this includes
the medical history, clinical examination, echocardiogram, X-
ray, MRI, coronary-angiography, and myocardial biopsy, as
well as laboratory data (BNP or NT-proBNP, CRP, hemoglobin,
sodium, potassium, creatinin, albumin, and if possible, plasma
levels of aldosterone, norepinephrine, angiotensin, renin, re-
spectively). Treatment success is monitored by the clinical
functional (NYHA, Ross I–IV) and nutritional status, heart
and respiratory rate, intermittent diastolic and systolic blood
pressure, and SaO2 measurements. Follow-up laboratory and
imaging data should be acquired.
Taking into account-specific exclusion criteria, at our institu-
tion, the chronic, age-independent heart failure therapy consists
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of specific long-acting ß1-adrenoreceptor blocker (bisoprolol),
long-acting tissue angiotensin-converting enzyme inhibitor
(lisinopril), and mineralocorticoid-receptor blocker
(spironolactone) and applying a goal-oriented drug dosage [43].
Digoxin is the fourth-line HF drug with a target of a plasma level
of 0.5–0.9 ng/ml. Chronic treatments with loop-diuretics are
avoided, and hydrochloro-thiazide in low dosages of 0.5–1 mg/
kg are applied once or twice per day, if really needed. If there are
signs of inappropriate ADH secretion with severe hyponatremia,
we currently use the V2-receptor antagonist, tolvaptan, once per
day in a dosage of 0.1–(0.3)mg/kg, targeting a sodium serum
level of 140–145 mmol/l. The hypothesized treatment goals for
treatment of LV-DCM with a highly specific ß1-BAR blocker,
tissue ACE inhibitor, and aldosterone-antagonist are summarized
in Table 2.
Considering the (patho-)physiology of the ß-adrenergic recep-
tors (ß-AR) in pediatric DCM, highly selective ß1-AR blockers
are recommended in children to treat chronic HF caused by LV-
DCM [34, 43, 50]. It is generally accepted that chronic stimula-
tion of the cardiac β1-adrenergic system is toxic to the heart and
contributes to the pathogenesis of congestive heart failure [11].
We could show that children that underwent open heart surgery
with cardiac arrest demonstrated a decreased ß-adrenoceptor-me-
diated adenylate cyclase activation in a manner compatible with
an uncoupling of ß-adrenoceptors from the Gs-protein-adenylate
cyclase complex [52]. Cardiac arrest and HF liberate
myocardially stored norepinephrine [47] and cause ß1-receptor
desensitization. As stated, chronic stimulation of β1-receptors is
cardiotoxic while β2-receptor stimulation might be cardio-
protective [8, 11]. The elegant study of Miyamoto et al. [33,
34] not only demonstrated the differences of BAR pathophysiol-
ogy between pediatric and adult patients with idiopathic dilated
cardiomyopathy but also recommended the use of ß1-selective
BAR blocker in children. The data byMiyamoto et al. might also
explain the failure of non-specific ß-blocking therapy in previous
clinical pediatric HF trials. Miyamoto et al. showed that ß1-ARs
are downregulated in both adults and children with chronic HF
but that the ß2-AR is downregulated only in pediatric DCM. She
stated BFurther inhibition of the already downregulated ß2-ARs
may override the benefit of ß1-AR inhibitor therapy, because
preservation of ß2-AR function is beneficial.^ In addition, sev-
eral studies support the cardio-protective effect of short-term be-
ta-2 stimulation [4, 5, 9, 17, 31, 32, 38, 45, 63]. Bisoprolol is a
long-acting, highly cardio-selective BAR-blocker, with a low
side effect profile. Bisoprolol has a beta1/beta2-specific binding
ratio of about 125, metoprolol of about 80, and propranolol and
carvedilol of about 5 [63]. Dual mechanism of action includes
selective beta1-receptor blockade and stimulation of endothelial
NO production [62]. Additionally, ß1-specific BAR-blockers can
block renal ß1-adrenergic receptors and concomitant renin
Fig. 2 Estimated survival and
freedom of death in children with
DCM [50]. Shown is the median
follow-up 16 months (range 2–
80 months) of 38 children in an
age less than 3 years admitted at
the Pediatric Heart Center
Giessen. The Kaplan-Meier sur-
vival curve after the diagnosis of
dilated cardiomyopathy revealed
a 1-year survival of 97 % and a 5-
year survival of 86 % [50]
Table 2 Summarizes the hypothetical aim of therapy and the used heart
failure drugs
1.Heart rate control in order to improve the ratio of (myocardial) oxygen
consumption to demand and prolong the time for diastolic ventricular
filling (ß1-specific ß-blocker)
2. Diminishing apoptosis and myocytes necrosis (ß1-specific ß-blocker)
3. Diminishing interstitial fibrosis by blocking sympathetic- and RAA-S
(three first-line drugs)
4. Reduction of cardiac afterload together with preservation of the
coronary perfusion pressure by adequate (preload) intravascular, in
particular, arterial vascular filling (avoidance of diuretics, effectively
dosed ACE-I + ß1-specific blocker, preserving the beta 2 receptor
function)
5.Basis for additional strategies to re-establish ventricular synchrony and
re-establish VVI as prerequisite for cardiac regeneration (all three first-
line drugs)
6. Low risk-benefit ratio and high parental compliance by daily single-
dose therapy together with easy dosing of 0.1–0.2 (0.3)mg/kg× day
for both bisoprolol and lisinopril and once application of
spironolactone 1–2 mg/kg× day, respectively
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release caused by HF or in association with ACE inhibitor ther-
apy [10].
Combined with ß1-adrenoreceptor blockers, long-acting tis-
sue angiotensin-converting enzyme inhibitors [57] like lisinopril
or ramipril are our age-independent HF drugs of choice, based on
the hypothesis that stimulated RAAS can be blocked by both
drugs acting synergistically to lower systemic vascular resistance
and avoid myocardial fibrosis, the latter together with the
mineralocorticoid-receptor blocker spironolactone.
In order to improve systemic blood flow, these drugs have
not only been recommended in HF patients with stable hemo-
dynamics [25], but also to transit unstable patients to a stable
hemodynamic status [43, 50, 53]. More recently, we are
treating all LV-DCM patients with the triple drug combination
in preparation for reversible pulmonary artery banding [43,
53]. Only patients with volume depletion due to overdiuresis
are excluded, but ongoing inotropic support is not a contrain-
dication for additional ß1-adrenoreceptor blockade, which
may facilitate successful weaning of inotropes. Clinical pa-
rameters and biomarkers monitor treatment success (Fig. 3).
Treatment compliance together with very low side effects, can
be impressive, as we could observe and document prior to and
immediately after reversible pulmonary arterial banding
(rPAB) as a novel therapy to treat LV-DCM [43, 53].
Additional questions arise: why is captopril typically recom-
mended as the first choice for HF treatment in infants and
enalapril an appropriate choice for those older than the age of
2 yea r s [24 ] ? I n i n f an t s and young ch i l d r en ,
bronchoconstriction and bronchiolitis are common and often
associated with HF. Thus, it is our view that non-specific
BAR blockers with a ß2-blocking effect and less-specific
ACE-I with a higher risk of bradykinin-dependent cough and
bronchoconstriction should be avoided. High renin and
creatinin levels together with hyponatremia are classical signs
not only of severe HF but also of inadequate diuretic therapy.
To lower the risk of a blood pressure drop after initiating vaso-
dilator therapy, there should not be a dosage reduction or with-
drawal of ACE-I therapy, but rather implementation of diuretics
[19, 20, 37, 44, 59].
Hyperdynamic HF related to a ventricular left-to-right
shunt
Surgical or transcatheter closure of a hemodynamically rele-
vant ventricle septum defect (VSD) is the treatment of choice.
However, there may be several reasons why such a curative
approach cannot be performed or need to be delayed.
Diuretics, digoxin, and fluid restriction are usually recom-
mended to treat chronic HF based on a left-right shunt, al-
though there is no data that document efficacy [12, 15, 42,
55]. This above management strategy is ill conceived because
diuretics, fluid restriction, and digoxin do not achieve the goal
of increasing systemic blood flow but instead favor the imbal-
ance of pulmonary and systemic blood flow [12, 13]. Diuretic-
and fluid restriction-dependent neuro-humoral stimulation
and digoxin-caused vasoconstriction increase the left-right
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Fig. 3 Shown is the mean brain natriuretic peptide (BNP) value of 20
infants and children younger than 3 years with left ventricular dilative
cardiomyopathy (LV-DCM) and preserved right ventricular ejection frac-
tion (pRV-EF), which were admitted for heart transplantation. The ex-
tremely high BNP values at admission decreased significantly [we be-
lieve as a consequence of the administered ‘triple therapy’] during the
period prior to surgical pulmonary banding (PAB). At admission, all
patients had been treated with in some high dosages of furosemide inde-
pendent of continuously administered inotropic treatment. Furosemide
was stopped and bisoprolol (B), lisionopril (L), and spironolactone (S)
were started. The goal was to achieve a resting heart rate (HR) of less than
120/min with an adequate systemic blood pressure to sufficient diuresis.
The inotropic treatment was continued, but if dobutamine had been part
of the pre-admission regiment, it was changed to the inodilator milrinone
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shunt; in mid-term, such treatment might be associated by
cardiac cachexia (Fig. 4). And as a reminder, in congenital
heart defects with left-right shunt, the systolic function of
the left ventricle is mostly preserved [13], whereas diastolic
function may be impaired. Older patients with a left-right
shunt develop commonly diastolic dysfunction caused by
the compensatory mechanism of left ventricular volume de-
pletion due to sympathetic and RAA stimulation. Again,
based on our own institutional experience of more than a
decade, bisoprolol without blocking the systemic vasodilation
favoring ß2-adrenoreceptor, highly specific tissue ACE-I, like
lisinopril and spironolactone, if diastolic dysfunction with pre-
served ejection fraction are present, should be and are used to
influence the balance of left-to-right shunt in order to favor
systemic blood flow. The improvement of chronic HF symp-
toms can be easily monitored by the decrease in heart and
Fig. 4 Represents L/R shunt of
hemodynamically relevant VSD;
infants and young children not
early surgically corrected, but
mid-term treated by diuretics and
fluid restriction develop as pic-
tured severe cachexia because L/
R shunt is favored by increased
systemic vascular resistance and
high oxygen consumption by
compensating increased heart and





DA-Flow systolic - diastolic
DA-Flow – pattern with diastolic L/R-shunt: 
Indication for Bisoprolol + Lisinopril
LAP RAP
Atrial pressures before IAS-Stent
Fig. 5 Shows the schematic picture of Hybrid stage I consisting of duct
stenting (DA stent), bilateral pulmonary banding (bPAB), and interatrial
septummanipulation by stent placement. Left atrial (LAP) decompression
to a pressure level of the right atrium (RAP) is an important part of a
balanced parallel turned pulmonary to systemic circulation. The
echocardiography shows an effective bPAB by its typical flow-pattern,
but despite an effective bPAB, the systolic right-to-left flow through the
duct is accompanied by a diastolic left-to-right reflow; one important
indication to reduce the systemic vascular resistance without jeopardizing
coronary blood flow. Additionally, bisoprolol reduces heart rate, which
improves single ventricle filling; all factors together diminish pulmonary
congestion, reduce total and myocardial oxygen consumption, and im-
prove the baby’s functional class
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respiratory rates, signs of less severe pulmonary congestion,
and improved food intake in infants. This therapeutic concept
avoids cardiac cachexia, which was usually observed in al-
most all patients in the past and is still observable today.
HF prophylaxis in hypoplastic left heart syndrome
after hybrid stage I
The right ventricle as the systemic heart chamber is usually
found in congenital malformations like congenital corrected
transposition of the great arteries (ccTGA) and also in the hy-
poplastic left heart syndrome (HLHS) and in the HLH-
complex; in HLHC, the right ventricle works in parallel with
an obstructed or borderline left ventricle. There is growing ev-
idence that RV dysfunction develops in many of those patients
and accounts for the considerable morbidity and mortality.
Therefore, systemic RV function needs close surveillance and
sufficient timing of an appropriate intervention to optimize out-
come. Almost dogmatically, HF medications, which have been
pronounced to be effective for the treatment of a failing left
ventricle, are judged to be ineffective for treating a failing sys-
temic right ventricle [24, 25]. However, we wish to point out
that the subpulmonary right or left ventricle is metabolically
differently active and this may have substantial implications
for the pharmacotherapy. Genes encoding drug-metabolizing
enzymes, like cytochrome P450 mono-oxygenases, are pre-
dominantly expressed in the subpulmonary heart chamber; this
might explain the lack of efficacy of drugs like angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers
on a subpulmonary RV or LV. An atrial switch of the venous
connection to the right and left atria reverses the messenger
RNA expression profiles. An anatomical left, but
subpulmonary positioned, ventricle shows the expression of
cytochrome P450 genes normally found in the subpulmonary
RV. These facts highlight the importance of the subpulmonary
ventricle and pulmonary circulation for the metabolic break-
down of drugs [58]. Thus, for the pharmacological response
more important than the morphology of the ventricle appears
to be its position. Such data are not available for univentricular
hearts, in particular prior to Fontan completion. Considering
HLHS, the right ventricle is responsible for the systemic and
pulmonary circulation, but following the surgical completion of
the Fontan circulation, the distally to the pulmonary circulation
positioned RV supports the systemic circulation.
At our institution, neonates born with HLHS and some pa-
tients with HLHC are palliated using the Giessen Hybrid ap-
proach which consists of bilateral pulmonary banding, duct
stenting, and, if necessary, atrial septum manipulation
(Fig. 5). This approach has been established more than 17 years
ago as an alternative to the Norwood stage I operation [54]. It is
our goal to reduce inter-stage morbidity and mortality; one part
of this inter-stage strategy is based on the use of dual or triple
therapy of bisoprolol with lisinopril and spironolactone. The
use of ß1-selective BAR blockers is further supported by re-
cently published data fromMiyamoto et al. [34], which stresses
the altered BAR signaling in HLHS [34]. During the last
5 years, we have routinely avoided diuretics or digoxin when
treating newborns or young infants discharged home after the
hybrid procedure. We monitor heart and respiratory rate (Video
1) and, intermittently, systolic and diastolic blood pressure. The
mean blood pressure should not be relied on simply because a
diminished systemic blood flow might remain undetected.
Echocardiographic and serum biomarkers (BNP, ProBNP)
ought to be used for additional, intermittent monitoring.
The blood pressure amplitude, together with the
echocardiographically estimated degree of diastolic left-to-
right shunt across the stented duct is important and supports
our medical strategy (Fig. 5). The effect of the drug therapy
on the systemic vascular resistance can be easily moni-
tored. Low heart rate, prolonged diastolic filling time,
and reduction of systemic vascular resistance (without
increasing retrograde aortic blood flow and jeopardizing
myocardial perfusion pressure) are the therapeutic goals.
Excellent parental compliance with a single-dose regi-
ment and the monitoring of body weight prior to hybrid
stage II are usually obtained. Whether out-of-proportion
myocardial hypertrophy of the systemic right ventricle
or interstitial fibrosis can also be reduced by our treat-
ment strategy remains to be examined in future studies.
In conclusion
Our clinical practice and institutional experience in chronic
HF treatment in infants and children with left ventricular
systolic heart failure, high-output failure due to significant
left-right shunting congenital heart diseases, as well as
HLHS and HLH-complex after hybrid stage I, are in clear
contrast to the official guidelines for chronic HF therapy
in infants and children. We acknowledge as a substantial
weakness that we are missing randomized study results;
however, in the absence of such trials, observational stud-
ies should receive credit as a first step. In addition, the
here illustrated chronic HF therapy can lay the ground for
a randomized multicenter studies designed to analyze the
efficacy of other endogenous repair mechanisms
supporting therapies as we advocated by pulmonary arte-
rial banding in selected young patients with DCM and
preserved right ventricular function.
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